Likmez FDA Approval History
Last updated by Judith Stewart, BPharm on Sep 29, 2023.
FDA Approved: Yes (First approved September 22, 2023)
Brand name: Likmez
Generic name: metronidazole
Dosage form: Oral Suspension
Previous Name: ATI-1501
Company: Appili Therapeutics Inc. and Saptalis Pharmaceuticals , LLC
Treatment for: Bacterial Infection, Trichomoniasis, Amebiasis
Likmez (metronidazole) is an oral liquid suspension formulation of the approved nitroimidazole antimicrobial metronidazole for the treatment of trichomoniasis, amebiasis, and anaerobic bacterial infections.
- Metronidazole is a well established and widely used frontline treatment for parasitic and anaerobic bacterial infections.
- The previously approved oral formulations of metronidazole are tablets, which have a bitter taste and can be problematic for people who have difficulty swallowing,
- Likmez is a proprietary taste-masked liquid suspension reformulation of metronidazole that is both pleasant tasting and easy to swallow. It addresses the needs of patients with dysphagia and avoids risks associated with drug compounding, and discontinuation related anti-microbial resistance.
- Warnings and precautions associated with Likmez include central and peripheral nervous system effects, and blood dyscrasias.
- Common adverse reactions include nausea, headache, anorexia, vomiting, diarrhea, abdominal cramping, epigastric distress, and constipation.
Development timeline for Likmez
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
